BackXenetic Biosciences Overview

Xenetic Biosciences Total Current Liabilities

Xenetic Biosciences's total current liabilities is $890K.

Get informed when a big investor buys or sells

+ Follow
Total Current Liabilities
$894977.00
0.94% YoYΔ $-8453.00 vs prior year quarter

Peer trimmed avg / median

Loading

Xenetic Biosciences Total Current Liabilities History

Loading

Xenetic Biosciences vs. peers: Total Current Liabilities Comparison

Loading

Xenetic Biosciences Total Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Xenetic Biosciences (XBIO) FAQ

Xenetic Biosciences's total current liabilities stands at $890K as of June 2026. That compares with $900K in the prior-year period — down 0.9% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Xenetic Biosciences reported $890K in total current liabilities versus $900K a year earlier — a 0.9% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $900K in the prior-year period — down 0.9% year over year. Sustained growth in total current liabilities can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Xenetic Biosciences's total current liabilities evolved across reporting periods, while the comparison chart places XBIO next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, total current liabilities is commonly used to spot outliers. Xenetic Biosciences's reading of $890K is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.